Ultra-hypofractionated versus Conventionally Fractionated Radiation Therapy Boost for Patients with High-Risk, Localized Prostate Cancer: A 5-Year Results from Randomized HYPO-PROST Trial

被引：0
|
作者：
Milecki, P., II [1 ,2 ]
Antczak, A. [3 ]
Milecki, T. [3 ]
Gluszak, P. [2 ]
Piotrowski, T. G. [2 ]
Rucinska, A. [2 ]
Malicki, J. [2 ]
机构：
[1] Poznan Univ Med Sci, Electroradiol Dept, Poznan, Poland
[2] Greater Poland Canc Ctr, PL-61866 Poznan, Poland
[3] Med Univ Poznan, Chair Urol, Poznan, Poland
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2020年 / 108卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
128
引用
收藏
页码：S62 / S63
页数：2
相关论文
共 50 条
  • [1] Dosimetric Comparison of Ultra-Hypofractionated and Conventionally Fractionated Radiation Therapy Boosts for Patients with High-Risk Prostate Cancer
    Piotrowski, Tomasz
    Yartsev, Slav
    Krawczyk, Jaroslaw
    Adamczyk, Marta
    Jodda, Agata
    Malicki, Julian
    Milecki, Piotr
    LIFE-BASEL, 2022, 12 (03):
  • [2] Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancer
    McDonald, Andrew M.
    Jacob, Rojymon
    Dobelbower, Michael C.
    Kim, Robert Y.
    Fiveash, John B.
    ACTA ONCOLOGICA, 2013, 52 (06) : 1181 - 1188
  • [3] Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT)
    Glicksman, Rachel M.
    Loblaw, Andrew
    Morton, Gerard
    Vesprini, Danny
    Szumacher, Ewa
    Chung, Hans T.
    Chu, William
    Liu, Stanley K.
    Tseng, Chia-Lin
    Correa, Rohann
    Deabreu, Andrea
    Mamedov, Alexandre
    Zhang, Liying
    Cheung, Patrick
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 119 (01): : 100 - 109
  • [4] Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
    Widmark, Anders
    Gunnlaugsson, Adalsteinn
    Beckman, Lars
    Thellenberg-Karlsson, Camilla
    Hoyer, Morten
    Lagerlund, Magnus
    Kindblom, Jon
    Ginman, Claes
    Johansson, Bengt
    Bjornlinger, Kirsten
    Seke, Mihajl
    Agrup, Mans
    Fransson, Per
    Tavelin, Bjorn
    Norman, David
    Zackrisson, Bjorn
    Anderson, Harald
    Kjellen, Elisabeth
    Franzen, Lars
    Nilsson, Per
    LANCET, 2019, 394 (10196): : 385 - 395
  • [5] Re: Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 Trial
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2020, 203 (01): : 32 - 32
  • [6] Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial
    Macias, Victor A.
    Barrera-Mellado, Inmaculada
    BJU INTERNATIONAL, 2020, 125 (02) : 215 - 225
  • [7] Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer
    He, Jiaoxue
    Wang, Qingfeng
    Hu, Qiancheng
    Li, Changlin
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [8] Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
    Lott, Felipe
    INTERNATIONAL BRAZ J UROL, 2020, 46 (06): : 1100 - 1101
  • [9] Hypofractionated versus conventionally fractionated external beam radiation therapy for localized prostate carcinoma: the results on late toxicity from prospective randomized trial
    Norkus, D.
    Miller, A.
    Karklelyte, A.
    Haverkamp, U.
    Prott, F.-J.
    Aleknavicius, E.
    Valuckas, K. P.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 : 37 - 38
  • [10] Hypo Versus Conventionally Fractionated 30CRT for High Risk Prostate Cancer: Updated Results of a Randomized Trial
    Saracino, B.
    Arcangeli, G.
    Strigari, L.
    Petrongari, M.
    Gomellini, S.
    Giordano, C.
    Ferraro, A.
    Landoni, V.
    Sanguineti, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S53 - S53
12345